|
|
||||||||
J Thorac Cardiovasc Surg 2005;130:1114-1121
© 2005 The American Association for Thoracic Surgery
Evolving Technology |
Division of Cardiothoracic Surgery, McGill University Health Center, Montreal, Quebec, Canada
Received for publication April 12, 2004; revisions received March 5, 2005; accepted for publication April 1, 2005. * Address for reprints: Dominique Shum-Tim, MD, Division of Cardiothoracic Surgery, The Montreal General Hospital, MUHC, 1650 Cedar Ave, Suite L9-513, Montreal, Quebec, H3G 1A4, Canada (Email: Dominique.Shum-Tim{at}muhc.mcgill.ca).
OBJECTIVE: It has been reported that unmatched adult bone marrow stromal cells could be tolerated by immune-competent allotransplant or xenotransplant recipients under various conditions. This study examined whether xenogeneic bone marrow stromal cells implanted immediately after myocardial infarction can survive and differentiate, attenuating deterioration in left ventricular function.
METHODS: In groups I and II (n = 34), myocardial infarctions were created in immunocompetent adult Lewis rats by proximal left coronary artery ligation. In group I, 3 x 106 lacZ-labeled mouse bone marrow stromal cells were immediately injected into the peri-infarct area of the left ventricle, whereas in group II, only culture medium was injected. There were 10 early and 4 late deaths. At 4 weeks after injection, hearts were stained for ß-galactosidase and troponin IC. In groups IIIA and IIIB, lacZ-labeled mouse skin fibroblasts were implanted into rat myocardium (n = 10 each) with and without left coronary artery ligation, respectively, and the rats were killed serially. In group IV, animals underwent sham surgery (n = 5, no deaths). At 4 weeks, surviving rats in groups I, II, and IV (n = 10, n = 10, and n = 5, respectively) underwent blinded transthoracic echocardiography for ventricular function studies.
RESULTS: In group I, labeled mouse-derived bone marrow stromal cells were found within rat myocardium that stained positively for troponin IC 4 weeks after implantation. Functionally, mean left ventricular ejection fraction (P = .007), stroke volume (P = .03), and fractional shortening (P = .02) were all significantly higher in group I than in group II. In groups IIIA and IIIB, mouse fibroblasts induced cellular infiltration with rapid loss of donor cells. No labeled cells were found after 4 days. In group IV, there was no change in cardiac function.
CONCLUSION: Xenogeneic bone marrow stromal cells implanted into acutely ischemic myocardium induced by coronary artery ligation were immunologically tolerated, survived and differentiated, resulting in a cardiac chimera which improved left ventricular function. This unique immunologic tolerance may suggest the feasibility of using bone marrow stromal cells as universal donor cells.
This article has been cited by other articles:
![]() |
A. M. Abarbanell, A. C. Coffey, J. W. Fehrenbacher, D. J. Beckman, J. L. Herrmann, B. Weil, and D. R. Meldrum Proinflammatory cytokine effects on mesenchymal stem cell therapy for the ischemic heart. Ann. Thorac. Surg., September 1, 2009; 88(3): 1036 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L Kao, W. Browder, and C. Li Cellular Cardiomyoplasty: What Have We Learned? Asian Cardiovasc Thorac Ann, January 1, 2009; 17(1): 89 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Atoui, D. Shum-Tim, and R. C.J. Chiu Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells" Ann. Thorac. Surg., July 1, 2008; 86(1): 327 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Hu, S. P. Yu, J. L. Fraser, Z. Lu, M. E. Ogle, J.-A. Wang, and L. Wei Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 799 - 808. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Atoui, J.-F. Asenjo, M. Duong, G. Chen, R. C.-J. Chiu, and D. Shum-Tim Marrow Stromal Cells as Universal Donor Cells for Myocardial Regenerative Therapy: Their Unique Immune Tolerance Ann. Thorac. Surg., February 1, 2008; 85(2): 571 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Makela, K. Ylitalo, S. Lehtonen, S. Dahlbacka, E. Niemela, K. Kiviluoma, J. Rimpilainen, H. Alaoja, T. Paavonen, P. Lehenkari, et al. Bone marrow derived mononuclear cell transplantation improves myocardial recovery by enhancing cellular recruitment and differentiation at the infarction site J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 565 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Wu, B. Zhou, C. T. Yu, B. Cui, S. H. Lu, Z. C. Han, and Y. L. Liu Therapeutic Potential of Human Umbilical Cord Derived Stem Cells in a Rat Myocardial Infarction Model Ann. Thorac. Surg., April 1, 2007; 83(4): 1491 - 1498. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Wu, Y. L. Liu, B. Zhou, and Z. C. Han Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 770 - 781. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |